TRIM51 BIOMARKER FOR PREDICTING MELANOMA TREATMENT RESISTANCE AND USE THEREOF

The present invention relates to a TRIM51 biomarker for predicting melanoma treatment resistance and a use thereof. As a result of verifying the effectiveness as a candidate for overcoming melanoma drug resistance through the regulation of TRIM51 mRNA or protein, and confirming whether it shows clin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	CHOI, Gil Don, CHO, Kyung Jin, LIM, Byung Ho
Format:	Patent
Sprache:	eng ; fre ; kor
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to a TRIM51 biomarker for predicting melanoma treatment resistance and a use thereof. As a result of verifying the effectiveness as a candidate for overcoming melanoma drug resistance through the regulation of TRIM51 mRNA or protein, and confirming whether it shows clinical significance as a treatment response prediction marker, melanoma-derived TRIM51 is very likely to find advantageous applications as a biomarker for predicting melanoma treatment response. La présente invention concerne un biomarqueur TRIM51 permettant de prédire la résistance au traitement contre le mélanome et son utilisation. Après avoir vérifié son efficacité en tant que candidat pour surmonter la résistance aux médicaments du mélanome par la régulation de l'ARNm ou de la protéine TRIM51, et confirmé sa signification clinique en tant que marqueur de prédiction de la réponse au traitement, TRIM51 dérivé du mélanome est très susceptible de trouver des applications avantageuses en tant que biomarqueur de prédiction de la réponse au traitement contre le mélanome. 흑색종 치료 내성 예측용 TRIM51 바이오마커 및 이의 용도에 관한 것으로써, 상기 TRIM51 mRNA 또는 단백질의 제어를 통해 흑색종 치료제 내성 극복 후보로서의 유효성을 검증하고, 치료 반응 예측 마커로서 임상적 유의성을 보이는지 확인한 결과, 흑색종 유래 TRIM51은 흑색종 치료 반응 예측을 위한 바이오마커로 유용하게 활용될 가능성이 매우 높은 장점이 있다.